BPA
CUE icon

Beacon Pointe Advisors’s Cue Biopharma CUE Stock Holding History

Beacon Pointe Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3K Buy
+333
New +$3.11K ﹤0.01% 1829
2025
Q3 		– Sell
-333
Closed -$6.82K – 1412
2025
Q2 		$6.82K Hold
333
– – ﹤0.01% 1248
2025
Q1 		$9.11K Hold
333
– – ﹤0.01% 1212
2024
Q4 		$10.9K Hold
333
– – ﹤0.01% 1196
2024
Q3 		$7.57K Hold
333
– – ﹤0.01% 1219
2024
Q2 		$12.4K Hold
333
– – ﹤0.01% 1259
2024
Q1 		$18.9K Hold
333
– – ﹤0.01% 1343
2023
Q4 		$26.4K Hold
333
– – ﹤0.01% 1306
2023
Q3 		$23K Hold
333
– – ﹤0.01% 1320
2023
Q2 		$36.5K Hold
333
– – ﹤0.01% 1068
2023
Q1 		$35.7K Hold
333
– – ﹤0.01% 1122
2022
Q4 		$28.5K Buy
+333
New +$30.5K ﹤0.01% 1048

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Beacon Pointe Advisors's CUE Position: Q1 2026 in Review

Beacon Pointe Advisors opened a new position in Cue Biopharma (CUE) in Q1 2026: 333 shares worth $2.3K. The stake represents ﹤0.01% of the portfolio and ranks #1829 among its holdings. This is a return to the name: Beacon Pointe Advisors previously reported a position in CUE as recently as Q2 2025.

Beacon Pointe Advisors first reported a position in CUE in Q4 2022 and has held it in 12 quarters since. The position peaked at $36.5K in Q2 2023. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

  • Beacon Pointe Advisors held 333 shares of Cue Biopharma worth $2.3K as of Q1 2026.
  • Cue Biopharma was a new Beacon Pointe Advisors position in Q1 2026.
  • Cue Biopharma made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1829 holding.
  • Beacon Pointe Advisors first reported a position in Cue Biopharma in Q4 2022 and has held it in 12 quarters since.
  • Beacon Pointe Advisors's Cue Biopharma position peaked at $36.5K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.